Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NUC-3373 in Combination With Standard Agents in Advanced Solid Tumours
NCT05714553Phase 2Terminated
- Sponsor
- NuCana
- Start
- Mar 2023
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of fosifloxuridine nafalbenamide in solid tumor (advanced stage), non-small cell lung cancer (NSCLC) and pleural mesothelioma (2 arms), sponsored by NuCana. Primary endpoint: Dose-Limiting Toxicities at 56 days. Started Mar 2023; status: terminated.
02
Drugs
fosifloxuridine nafalbenamide
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)pleural mesothelioma
Beyond the preview
Go deeper on NCT05714553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05714553.